The current issue of Evidence-Based Oncology™, a publication of The American Journal of Managed Care®, examines how new reimbursement models are making cancer care more patient-centered, but making those models sustainable is challenging.
Changing cancer care payment models are rewarding doctors and practices for making care more patient-centered, but the transition isn’t easy, according to the current issue of Evidence-Based Oncology™ (EBO™), a publication of The American Journal of Managed Care®. The issue can be found here.
While there have been wondrous innovations in both therapy and practice, cancer care is not yet cost-effective and affordable for everyone, writes Joseph Alvarnas, MD, editor-in-chief of EBO™ and director of Value-Based Analytics at City of Hope, in Duarte, California.
“While we understand the right sensibilities in creating a sustainable care delivery, we have not yet created the ideal model for delivering this consistently, at scale, across a nation of more than 325 million individuals,” Alvarnas writes.
Perspectives on moving to value-based models include:
About The American Journal of Managed Care®:
The American Journal of Managed Care® (AJMC®) is a peer-reviewed, MEDLINE-indexed journal that keeps readers on the forefront of health policy by publishing research relevant to industry decision makers as they work to promote the efficient delivery of high-quality care. AJMC.com is the essential website for managed care professionals, distributing industry updates daily to leading stakeholders. Other titles in the AJMC® family include The American Journal of Accountable Care®, and two evidence-based series, Evidence-Based Oncology™and Evidence-Based Diabetes Management™. These comprehensive offerings bring together stakeholder views from payers, providers, policymakers and other industry leaders in managed care. To order reprints of articles appearing in AJMC® publications, please contact Jeff Prescott at 609-716-7777, ext. 331.
Contacts:
AJMC® Media:
Theresa Burek, 609-716-7777
or
Surabhi Verma
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More